新光藥業(300519.SZ)擬使用部分募集資金在杭州市錢塘新區投設全資子公司
格隆匯 3 月 1日丨新光藥業(300519.SZ)公佈,為了充分利用杭州醫藥港的區位優勢和產學研的協同效應,有助於公司吸引高端技術人才,提高產品研發效率並有效降低研發成本,公司擬調整使用部分募集資金在杭州市錢塘新區杭州醫藥港和達藥谷(四期)設立全資子公司浙江新光醫藥科技有限公司(擬名),建設現代中藥研發中心建設項目,負責藥品研發、註冊、銷售等工作。
擬設立子公司浙江新光醫藥科技有限公司;註冊資本(擬):人民幣3,500.00萬元;經營範圍(擬):研發及銷售:中成藥、保健食品、藥品、食品、醫療器械技術、衞生用品、醫療美容用品、生物製品、高新生物技術、技術類科研產品;諮詢:健康產品信息、生物技術、試驗檢測技術。
公司此次對外投資是為了充分利用杭州醫藥港的區位優勢和產學研的協同效應,有助於公司吸引高端技術人才,提高產品研發效率並有效降低研發成本。公司通過建設現代中藥研發中心建設項目,逐步調整杭州、嵊州兩個研發中心的專業分工,合理配置資源,未來嵊州廠區內的研發中心將主要負責產品的工藝改進和成果轉化工作,並通過對現有生產技術、生產工藝的改進、優化和創新等各項措施,為公司後續生產提供技術支持,而藥品研發和註冊的工作將從嵊州研發中心剝離,轉由杭州現代中藥研發中心平台負責。
公司此次投資設立全資子公司的資金一部分來源於公司首次公開發行股票的募集資金,以原募集資金投資項目“營銷網絡建設項目”尚未使用資金2541.72萬元變更至本項目,“研發質檢中心建設項目”部分資金744.76萬元,合計3286.48萬元,不足部分由公司自籌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.